Amgen discounts cholesterol drug, but payers want more

New York

AMGEN Inc sells its cholesterol-lowering drug Repatha at a discount of about 30 per cent to its US list price of US$14,000 a year, but the largest pharmacy benefit managers say they want lower prices after new data suggested more patients should be treated with the drug.

Amgen, which on Friday presented data showing for the first time that Repatha cuts the ris…